Table of Contents
Chromatography Research International
Volume 2011, Article ID 632820, 6 pages
http://dx.doi.org/10.4061/2011/632820
Research Article

Development of LC Method for the Simultaneous Determination of Antidepressant Drug Combination Melitracen Hydrochloride and Flupentixol Dihydrochloride in their Combined Dosage Form

1Department of Pharmaceutical Chemistry and Analysis, Indukaka Ipcowala College of Pharmacy, Beyond GIDC, P.B. no. 53, New Vallabh Vidyanagar 388 121, India
2Sophisticated Instrumentation Centre for Applied Research and Testing, Vallabh Vidyanagar 388 120, India

Received 18 December 2010; Revised 29 March 2011; Accepted 4 April 2011

Academic Editor: Irene Panderi

Copyright © 2011 Usmangani K. Chhalotiya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A simple, specific and stability-indicating reversed-phase high-performance liquid chromatographic method was developed for the simultaneous determination of melitracen hydrochloride and flupentixol dihydrochloride in tablet dosage form. A Brownlee C-18, 5 μm column having 2 5 0 × 4 . 6  mm i.d. in isocratic mode, with mobile phase containing 0.025 M potassium dihydrogen phosphate: methanol (10 : 90, v/v; pH 7.3) was used. The flow rate was 1.0 mL/min, and effluents were monitored at 230 nm. The retention times of melitracen hydrochloride and flupentixol dihydrochloride were 7.75 min and 5.50 min, respectively. The linearity for melitracen hydrochloride and flupentixol dihydrochloride were in the range of 0.5–60 μg/mL. The recoveries obtained for melitracen hydrochloride and flupenthixol dihydrochloride was 99.81–100.77% and 99.42–100.12%, respectively. Both the drugs were subjected to acid and alkali hydrolysis, chemical oxidation, and dry heat degradation and photodegradation. The proposed method was validated and successfully applied to the estimation of melitracen hydrochloride and flupentixol dihydrochloride in combined tablet dosage form.